After 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasum’s Phase 3 Data

After 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasum’s Phase 3 Data

Our analysis concludes Corbus Pharmaceuticals Holdings, Inc. (CRBP) is materially undervalued, by at least a factor of 2X, if Lenabasum’s Phase 3 top-line data due “this summer” is strong enough to l…
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *